摘要
目的:探讨金荞麦片联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床效果。方法:选取2018年10月~2020年5月期间本院收治的88例COPD急性加重期患者,采用随机数字表法分为对照组与观察组,两组均给予基础药物配合呼吸机通气治疗,对照组在此基础上给予噻托溴铵粉雾剂治疗,观察组在对照组治疗基础上加服金荞麦片,两组均治疗2周。对比两组治疗前后的COPD评估量表测试评分(CAT)、6分钟步行距离、血气分析指标、临床疗效、血清炎症因子水平及不良反应发生率。结果:两组治疗后的CAT评分均降低,且观察组低于对照组(P<0.05);6分钟步行距离均提高,且观察组高于对照组(P<0.05)。两组治疗后动脉氧分压(PaO_(2))、动脉氢离子浓度(pH)均升高,且观察组高于对照组(P<0.05);动脉二氧化碳分压(PaCO_(2))均降低,且观察组低于对照组(P<0.05)。观察组治疗总有效率高于对照组(P<0.05)。两组治疗后血清超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平均降低,且观察组均低于对照组(P<0.05)。两组不良反应发生率比较无统计学差异(P>0.05)。结论:金荞麦片联合噻托溴铵粉雾剂临床疗效较佳,安全性高,可有效改善COPD急性加重期患者的临床症状和血气分析指标,减轻炎症反应。
Objective:To investigate the clinical effects of Jinqiaomai tablets combined with tiotropium bromide powder for inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:A total of 88 patients with acute exacerbation of COPD treated in our hospital were selected as research subjects,and randomly divided into the control group and the observation group.Both groups were treated with basic drugs combined with ventilator ventilation.On this basis,the control group was supplemented with tiotropium bromide powder for inhalation.The observation group was treated with Jinqiaomai tablets on the basis of the control group.Both groups were treated for 2 weeks.The COPD assessment test scores(CAT),6-minute walking distance,blood gas analysis index,clinical efficacy,serum inflammatory factor level and incidence of adverse reactions were compared between the two groups before and after treatment.Results:After treatment,CAT scores in both groups were lower and the observation group was lower than the control group(P<0.05).The 6-minute walking distance of the observation group was longer than the control group(P<0.05).After treatment,arterial partial pressure of oxygen(PaO_(2))and arterial hydrogen ion concentration(pH)of the two groups were increased(P<0.05),and the observation group was higher than the control group(P<0.05).Arterial partial pressure of carbon dioxide(PaCO_(2))in both group was decreased and the observation group was lower than the control group(P<0.05).The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of serum hypersensitive C reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in both groups were decreased(P<0.05),while those in the observation group were lower than those in the control group(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05).Conclusion:Jinqiaomai tablets combined with tiotropium bromide powder for inhalation has better clinical efficacy and higher safety,which can effectively improve the clinical symptoms and blood gas analysis indexes of patients with acute exacerbation of COPD,and reduce inflammatory response.
作者
李晓琳
吴景硕
刘正
朱惠源
张钟
LI Xiao-lin;WU Jing-shuo;LIU Zheng;ZHU Hui-yuan;ZHANG Zhong(Department of Respiratory and Critical Care Medicine,Zhengzhou Second People’s Hospital,Zhengzhou 450000,China)
出处
《中国合理用药探索》
2022年第4期59-64,共6页
Chinese Journal of Rational Drug Use
关键词
金荞麦片
噻托溴铵粉雾剂
慢性阻塞性肺疾病
急性加重期
临床疗效
Jinqiaomai tablets
tiotropium bromide powder for inhalation
chronic obstructive pulmonary disease
acute exacerbation
clinical efficacy